CROs/Service Providers

IQVIA launches secondary public offering and repurchase of common stock

Friday, December 1, 2017

IQVIA Holdings announced the launch of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Leonard Green & Partners, L.P. (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,500,000 shares (the “Repurchase”). The Repurchase will be completed outside IQVIA’s existing share repurchase program, under which IQVIA has approximately $195 million of remaining availability.

[Read More]

ICON launches FIRECREST Pre-Screen

Tuesday, November 28, 2017

ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, announced the launch of FIRECREST Pre-Screen, an innovative digital solution that increases the efficiency and quality of initial patient eligibility assessments. FIRECREST Pre-Screen provides a more robust solution for site personnel to identify potentially eligible patients which can lead to improved enrolment rates and reduced costs by preventing ineligible patients from progressing to the full screening stage.

[Read More]

CPi Global CRO added as SCRS new global impact partner

Monday, November 27, 2017

The Society for Clinical Research Sites (SCRS) announced that CPi Global CRO has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides a unique opportunity for sponsors, CROs and vendors to engage with SCRS and its members in an impactful manner. Becoming a GIP demonstrates CPi Global CRO’s commitment to clinical research sites. GIPs develop a deeper understanding of the needs of clinical research sites, and contribute to the development and implementation of Best Site Practices.

[Read More]

ACRO urges modernization of the R&D Tax Credit

Wednesday, November 22, 2017

As the Senate begins debate on a tax reform bill, the clinical research industry hopes that attention will be given to a small but substantive issue—updating a tax code provision that has had strong bipartisan support for more than 30 years.

[Read More]

Science Exchange, Alector partner

Monday, November 20, 2017

Science Exchange, a secure enterprise platform and aggregator for outsourced research and development (R&D), announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

[Read More]

Quotient Sciences acquires U.K CDMO Pharmaterials

Wednesday, November 15, 2017

Quotient Sciences, a drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K. The acquisition strengthens and expands Quotient’s formulation and manufacturing services footprint in the U.K., and further supports the growth of Quotient’s Translational Pharmaceutics platform, following the acquisitions of SeaView Research and QS Pharma in February 2017.

[Read More]

QuintilesIMS is now IQVIA

Monday, November 6, 2017

QuintilesIMS will be changing its name to IQVIA, a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for their patients. Beginning on November 15, 2017, equity shares of the company will trade on the NYSE under the new name and new ticker symbol “IQV.” Until then, IQVIA will continue to be listed under QuintilesIMS and symbol “Q” per the listing notification requirements of the NYSE. 

[Read More]